Arbutus Biopharma Corp. (ABUS) NASDAQ
$2.60 0.11 (4.42%)
Market Cap: $463.09M
As of 03/28/24 04:00 PM EDT. Market closed.
Arbutus Biopharma Corp. (ABUS)
NASDAQ
$2.60
0.11 (4.42%)
Market Cap: $463.09M
As of 03/28/24 04:00 PM EDT. Market closed.
arbutus biopharma corporation (nasdaq:abus) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis b infection, a disease of the liver caused by hepatitis b virus (hbv). we are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a ... read more
arbutus biopharma corporation (nasdaq:abus) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis b infection, a disease of the liver caused by hepatitis b virus (hbv). we are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the hbv treatment landscape and cure hepatitis b virus disease. in addition to our hbv assets, we are developing a pipeline of programs that leverage our expertise in rna interference (rnai) therapeutics and our lipid nanoparticle (lnp) technology. read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Sims Karen | Chief Medical Officer | Feb 02, 2024 | Sale | $2.31 | 4,358 | 10,078 | 125,542 | Feb 05, 2024, 07:55 PM |
HASTINGS DAVID C | Chief Financial Officer | Feb 02, 2024 | Sale | $2.31 | 9,593 | 22,184 | 181,907 | Feb 05, 2024, 07:54 PM |
Sofia Michael J. | Chief Scientific Officer | Feb 02, 2024 | Sale | $2.31 | 9,982 | 23,083 | 1,485,121 | Feb 05, 2024, 07:54 PM |
McElhaugh Michael J. | Interim President & CEO | Feb 02, 2024 | Sale | $2.31 | 10,164 | 23,504 | 1,504,793 | Feb 05, 2024, 07:54 PM |
Sofia Michael J. | Chief Scientific Officer | Dec 01, 2021 | Sale | $5.09 | 200,000 | 1,018,000 | 1,303,403 | Dec 03, 2021, 04:02 PM |
McElhaugh Michael J. | Chief Business Officer | Feb 09, 2021 | Sale | $5.00 | 20,000 | 100,000 | 1,307,457 | Feb 10, 2021, 05:06 PM |
McElhaugh Michael J. | Chief Business Officer | Dec 14, 2020 | Sale | $5.00 | 40,000 | 200,032 | 1,337,457 | Dec 16, 2020, 04:33 PM |
McElhaugh Michael J. | Chief Business Officer | Jul 23, 2020 | Sale | $5.01 | 20,000 | 100,200 | 1,367,457 | Jul 27, 2020, 05:27 PM |
Murray Mark J. | Director | Nov 28, 2018 | Option Exercise | $1.35 | 25,000 | 33,750 | 341,396 | Nov 30, 2018, 04:55 PM |
Sofia Michael J. | Chief Scientific Officer | Aug 13, 2018 | Sale | $9.51 | 4,250 | 40,436 | 167,162 | Aug 15, 2018, 03:14 PM |
Sofia Michael J. | Chief Scientific Officer | Aug 13, 2018 | Sale | $9.51 | 4,250 | 40,436 | 1,499,153 | Aug 14, 2018, 06:23 PM |
Sofia Michael J. | Chief Scientific Officer | Jul 11, 2018 | Sale | $10.00 | 10,000 | 100,000 | 1,503,403 | Jul 13, 2018, 01:36 PM |
Sofia Michael J. | Chief Scientific Officer | Jul 09, 2018 | Sale | $8.91 | 10,000 | 89,060 | 1,513,403 | Jul 10, 2018, 01:11 PM |
Sofia Michael J. | Chief Scientific Officer | Jul 06, 2018 | Sale | $8.45 | 10,000 | 84,500 | 1,523,403 | Jul 10, 2018, 01:11 PM |
Sofia Michael J. | Chief Scientific Officer | Jul 05, 2018 | Sale | $8.40 | 10,000 | 84,000 | 1,533,403 | Jul 06, 2018, 04:05 PM |
Sofia Michael J. | Chief Scientific Officer | Jul 03, 2018 | Sale | $8.00 | 10,000 | 80,000 | 1,543,403 | Jul 06, 2018, 04:05 PM |
Murray Mark J. | President & CEO | Apr 17, 2018 | Option Exercise | $0.35 | 27,007 | 9,560 | 316,396 | Apr 17, 2018, 08:22 PM |
Sofia Michael J. | Chief Scientific Officer | Oct 03, 2017 | Sale | $8.00 | 10,000 | 80,000 | 1,553,403 | Oct 05, 2017, 06:34 PM |
Sofia Michael J. | Chief Scientific Officer | Aug 15, 2017 | Sale | $3.70 | 30,000 | 111,000 | 191,412 | Aug 17, 2017, 07:41 PM |
Abrams Michael J. | Managing Director | Aug 16, 2016 | Option Exercise | $0.35 | 14,178 | 4,898 | 42,097 | Aug 18, 2016, 06:11 PM |
Murray Mark J. | President & CEO | Jun 16, 2016 | Option Exercise | $2.57 | 5,000 | 12,844 | 289,389 | Jun 20, 2016, 08:33 PM |
Murray Mark J. | President & CEO | Sep 11, 2015 | Option Exercise | $0.44 | 219,428 | 97,514 | 284,389 | Sep 15, 2015, 04:20 PM |
Abrams Michael J. | Managing Director | Sep 11, 2015 | Option Exercise | $0.44 | 17,044 | 7,574 | 27,919 | Sep 15, 2015, 04:18 PM |
HENRIQUES RICHARD C JR | Director | Aug 24, 2015 | Buy | $6.95 | 1,000 | 6,950 | 1,000 | Aug 26, 2015, 01:29 PM |
Owner | Relationship | Date | Value($) |
Sims Karen | Chief Medical Officer | 02/02/2024 | 10,078 |
HASTINGS DAVID C | Chief Financial Officer | 02/02/2024 | 22,184 |
Sofia Michael J. | Chief Scientific Officer | 02/02/2024 | 23,083 |
McElhaugh Michael J. | Interim President & CEO | 02/02/2024 | 23,504 |
Sofia Michael J. | Chief Scientific Officer | 12/01/2021 | 1,018,000 |
McElhaugh Michael J. | Chief Business Officer | 02/09/2021 | 100,000 |
McElhaugh Michael J. | Chief Business Officer | 12/14/2020 | 200,032 |
McElhaugh Michael J. | Chief Business Officer | 07/23/2020 | 100,200 |
Murray Mark J. | Director | 11/28/2018 | 33,750 |
Sofia Michael J. | Chief Scientific Officer | 08/13/2018 | 40,436 |
Sofia Michael J. | Chief Scientific Officer | 08/13/2018 | 40,436 |
Sofia Michael J. | Chief Scientific Officer | 07/11/2018 | 100,000 |
Sofia Michael J. | Chief Scientific Officer | 07/09/2018 | 89,060 |
Sofia Michael J. | Chief Scientific Officer | 07/06/2018 | 84,500 |
Sofia Michael J. | Chief Scientific Officer | 07/05/2018 | 84,000 |
Sofia Michael J. | Chief Scientific Officer | 07/03/2018 | 80,000 |
Murray Mark J. | President & CEO | 04/17/2018 | 9,560 |
Sofia Michael J. | Chief Scientific Officer | 10/03/2017 | 80,000 |
Sofia Michael J. | Chief Scientific Officer | 08/15/2017 | 111,000 |
Abrams Michael J. | Managing Director | 08/16/2016 | 4,898 |
Murray Mark J. | President & CEO | 06/16/2016 | 12,844 |
Murray Mark J. | President & CEO | 09/11/2015 | 97,514 |
Abrams Michael J. | Managing Director | 09/11/2015 | 7,574 |
HENRIQUES RICHARD C JR | Director | 08/24/2015 | 6,950 |
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
BLACKROCK INC. | 10,390,300 | 0.00066% | 1.13% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 2,817,695 | 0.00074% | 4.47% | Other |
AQR CAPITAL MANAGEMENT LLC | 40,598 | 0.00017% | Exited | Other |
Period of Report: 12/31/2023
10-K/10-Q Filings: View